Ir al contenido
The information contained in this website is intended for International Health Care Professionals. Patients, please refer to your physician for information.
  • About Us
    • Brand History
    • History of P4HB
  • What is GalaFLEX?
    • Instructions for Use
    • What is P4HB?
    • Properties
    • The Scaffold Collection
      • GalaFLEX®
      • GalaFLEX 3D TM
      • GalaFLEX 3DR TM
    • Information for your patient
  • Publications
  • Contact Us
    • Locations
Menú
  • About Us
    • Brand History
    • History of P4HB
  • What is GalaFLEX?
    • Instructions for Use
    • What is P4HB?
    • Properties
    • The Scaffold Collection
      • GalaFLEX®
      • GalaFLEX 3D TM
      • GalaFLEX 3DR TM
    • Information for your patient
  • Publications
  • Contact Us
    • Locations
The information contained in this website is intended for International Health Care Professionals. Patients, please refer to your physician for information.

Publications

Comparison of the host macrophage response to synthetic and biologic surgical meshes used for ventral hernia repair

Catalina Pineda Molina, Ross Giglio, Riddhi M. Gandhi, Brian M. Sicaria, Ricardo Londono, George S. Hussey, Joseph G. Bartolacci, Lina M. Quijano Luquea, Madeline C. Cramerm, Jenna L. Dziki, Peter M.Crapo, Stephen F. Badylak
Journal of Immunology and Regenerative Medicine Volume 3, Pages 13-25
Link to Publication: https://www.sciencedirect.com/science/article/abs/pii/S2468498818300192

Abstract

The host innate immune response to a surgical mesh is arguably the most important determinant of tissue remodeling and functional outcome. Macrophage phenotype and the associated secretion of pro-inflammatory or anti-inflammatory cytokines during the first 10–14 days following implantation has been strongly associated with downstream events such as chronic inflammation vs. functional tissue remodeling, respectively, and the associated clinical consequences. A persistent, pro-inflammatory (M1-like) macrophage phenotype is typically associated with fibrosis and scarring. In contrast, an early transition to a regulatory, pro-remodeling (M2-like) macrophage phenotype is predictive of organized, site-appropriate connective tissue deposition. The ratio of M2-like to M1-like macrophages in the early post-implantation period defines the microenvironmental milieu and the associated tissue response. The present study evaluated the early macrophage response to a synthetic nonresorbable (Bard® Mesh), synthetic resorbable (TIGR® Matrix Surgical Mesh and GORE® BIO-A® Tissue Reinforcement), synthetic mesh composed of the naturally occurring molecule 4-hydroxybutyrate, (Phasix™ Mesh), and a biologic surgical mesh composed of dermal extracellular matrix (Strattice™ Reconstructive Tissue Matrix); all of which are used in ventral hernia repair. The spatiotemporal distribution of pro-inflammatory (CD68+CD86+TNF-α+) and pro-remodeling (CD68+CD206+) macrophages, and the remodeling response in terms of vascularization, total number of infiltrating cells, presence of multinucleate giant cells (MNGC), and cell layer thickness around the implanted materials was evaluated at 3, 7, 14, 21, and 35 days post implantation. Results showed an association of the synthetic non-resorbable and resorbable meshes with a robust, pro-inflammatory response within 3 days of implantation, and an increased presence of MNGC around the mesh fibers at longer time points. Phasix™ Mesh was associated with an increased presence of M2-like macrophages immediately adjacent to the mesh fibers at earlier time points, and a favorable tissue remodeling outcome at 35 days. Results of the present study are consistent with the premise that an early shift of M1-like to M2-like macrophages is associated with favorable outcomes, including reduced fibrosis, at later time points.

Authors and Funding

Catalina Pineda Molina was supported by the Colciencias-Fulbright Scholarship and the Tuition Remission Fellowship (TRF) from The Center for Latin American Studies (CLAS) at the University of Pittsburgh. The authors thank Lori Walton from the Histology Center at the McGowan Institute for Regenerative Medicine for histologic section preparation and the center for Biologic Imaging at the University of Pittsburgh for access to imaging facilities. Partial funding of this study was provided by CR Bard, Inc.

  • Home
  • About Us
  • What is GalaFLEX?
  • Publications
  • Contact
Menú
  • Home
  • About Us
  • What is GalaFLEX?
  • Publications
  • Contact

See instructions for use here

+ Show References
+ Show patents
Twitter Instagram Linkedin Facebook
Galatea Surgical© 2023. All Rights reserved 500075 Rev B
  • Terms of Use
  • Privacy Policy
Menú
  • Terms of Use
  • Privacy Policy
+ Show References
+ Show patents
Twitter Instagram Linkedin Facebook
Galatea Surgical© 2023. All Rights reserved 500075 Rev DB
  • Terms of Use
  • Privacy Policy
  • Terms of Use
  • Privacy Policy
Important Cookie Information – This message will only appear once. Galatea Surgical website uses cookies. By continuing to browse the site, you are agreeing to the use of cookies.
Read Privacy Policy ACCEPT
Manage consent

Privacy Overview

Read Privacy Policy

Necessary
Siempre activado
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
GUARDAR Y ACEPTAR
The information contained in this website is intended for International Health Care Professionals. Patients, please refer to your physician for information.
  • Home
  • About Us
  • What is GalaFLEX?
  • Publications
  • Contact
  • Home
  • About Us
  • What is GalaFLEX?
  • Publications
  • Contact